Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy

Cancer Gene Therapy

Volumn 20, Issue 7, 2013, Pages 386-393

  Karlsson, S C H ^a   Lindqvist, A C ^a   Fransson, M ^a   Paul Wetterberg, G ^a   Nilsson, B ^a   Essand, M ^a   Nilsson, K ^a   Frisk, P ^b   Jernberg Wiklund, H ^a   Loskog, S I A ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

ABT 737; Bcl 2; BH3 mimetics; CAR; Engineered T cells; Pre B ALL

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; CASPASE 3; CASPASE 7; CD19 ANTIGEN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; APOPTOSIS; ARTICLE; CANCER CELL; CELL METABOLISM; CHILD; DAUDI CELL; DRUG EFFICACY; DRUG TARGETING; HUMAN; HUMAN CELL; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR; T LYMPHOCYTE; WESTERN BLOTTING;

ANTIGENS, CD19; ANTIGENS, CD86; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIPHENYL COMPOUNDS; CELL LINE, TUMOR; COCULTURE TECHNIQUES; COMBINED MODALITY THERAPY; CYTOTOXICITY, IMMUNOLOGIC; GENE EXPRESSION; HLA ANTIGENS; HUMANS; IMMUNOTHERAPY; INTERCELLULAR ADHESION MOLECULE-1; NITROPHENOLS; PHENOTYPE; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; SULFONAMIDES; T-LYMPHOCYTES;

EID: 84880923283     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2013.35     Document Type: Article

References (26)

1. Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009; 15: 1126-1132.
2. Cillessen SA, Meijer CJ, Notoya M, Ossenkoppele GJ, Oudejans JJ. Molecular targeted therapies for diffuse large B-cell lymphoma based on apoptosis profiles. J Pathol 2010; 220: 509-520.
3. Vogler M, Dinsdale D, Dyer MJ, Cohen GM. Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ 2009; 16: 360-367.
4. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681. (Pubitemid 40825512)
5. High LM, Szymanska B, Wilczynska-Kalak U, Barber N, O'Brien R, Khaw SL et al. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol Pharmacol 2010; 77: 483-494.
6. Khaw SL, Huang DC, Roberts AW. Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies. Pathology 2011; 43: 525-535.
7. Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010; 11: 1149-1159.
8. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010; 116: 4099-4102.
9. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 2011; 121: 1822-1826.
10. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2011; 119: 2709-2720.
11. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3: 95ra73.
12. Cullen SP, Brunet M, Martin SJ. Granzymes in cancer and immunity. Cell Death Differ 2010; 17: 616-623.
13. Klein E, Klein G, Nadkarni JS, Nadkarni JJ, Wigzell H, Clifford P. Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res 1968; 28: 1300-1310.
14. Dyer MJ, Fischer P, Nacheva E, Labastide W, Karpas A. A new human B-cell non-Hodgkin's lymphoma cell line (Karpas 422) exhibiting both t (14;18) and t(4;11) chromosomal translocations. Blood 1990; 75: 709-714. (Pubitemid 20069213)
15. Ben-Bassat H, Goldblum N, Mitrani S, Goldblum T, Yoffey JM, Cohen MM et al. Establishment in continuous culture of a new type of lymphocyte from a 'Burkitt like' malignant lymphoma (line D.G.-75). Int J Cancer 1977; 19: 27-33. (Pubitemid 8016922)
16. Hiraki S, Miyoshi I, Kubonishi I, Matsuda Y, Nakayama T, Kishimoto H et al. Human leukemic 'null' cell line (NALL-1). Cancer 1977; 40: 2131-2135. (Pubitemid 8239702)
17. Nilsson K, Sundstrom C. Establishment and characteristics of two unique cell lines from patients with lymphosarcoma. Int J Cancer 1974; 13: 808-823.
18. Chen R, Plunkett W. Strategy to induce apoptosis and circumvent resistance in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol 2010; 23: 155-166.
19. Wu LX, La Rose J, Chen L, Neale C, Mak T, Okkenhaug K et al. CD28 regulates the translation of Bcl-xL via the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway. J Immunol 2005; 174: 180-194. (Pubitemid 40007404)
20. Cillessen SA, Hess CJ, Hooijberg E, Castricum KC, Kortman P, Denkers F et al. Inhibition of the intrinsic apoptosis pathway downstream of caspase-9 activation causes chemotherapy resistance in diffuse large B-cell lymphoma. Clin Cancer Res 2007; 13: 7012-7021. (Pubitemid 350276882)
21. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
22. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006; 10: 389-399. (Pubitemid 44711953)
23. Lin X, Morgan-Lappe S, Huang X, Li L, Zakula DM, Vernetti LA et al. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene 2007; 26: 3972-3979. (Pubitemid 46884293)
24. Tahir SK, Yang X, Anderson MG, Morgan-Lappe SE, Sarthy AV, Chen J et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res 2007; 67: 1176-1183.
25. Song JH, Kandasamy K, Kraft AS. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J Biol Chem 2008; 283: 25003-25013.
26. Begley J, Vo DD, Morris LF, Bruhn KW, Prins RM, Mok S et al. Immunosensitization with a Bcl-2 small molecule inhibitor. Cancer Immunol Immunother 2009; 58: 699-708.